Prospective Episealer® Talus clinical study fully recruited
Episurf Medical (Nasdaq: EPIS B) today announces that all patients have been recruited to a prospective clinical study on the Episealer Talus® implant, led by Prof. Stefano Zaffagnini, from the Rizzoli Orthopaedic Institute in Bologna, Italy, supported by Dr Massimiliano Mosca and Prof. Niek van Dijk.
The study will follow 20 patients who received an Episealer Talus® implant as treatment for osteochondral defects in their ankle joint. Episealer® Talus is Episurf Medical’s CE marked implant technology, intended for the treatment of ankle lesions.
“Our technology for ankle lesions is getting more and more attention internationally and we are very pleased that this study is fully recruited. The study started under difficult conditions during the pandemic, but the recruitment has now been concluded in a very efficient way. We are looking forward to the results, and it is, as always, an honour to work with the prestigious Rizzoli Orthopaedic Institute in Bologna,” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 10:00 CEST on 13 September 2023.
Tags: